March 2013

While Congress worries about physicians’ salaries and employers bemoan the cost of imaging, it’s orphan drugs that might deserve most attention
Ed Silverman

Many who claim to be constructing such entities are really creating ‘clinically integrated organizations’

Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD
Scott Guerin, PhD
Everything is relative, but there’s been what many experts describe as substantial growth for a lot reasons
John Carroll

These tools, often adopted by other industries, can help insurers improve health care delivery

Preetinder S. Gill
A controversial study challenges backers to prove that these technologies are cost-effective
Frank Diamond

An MCO with an integrated medical and pharmacy benefit management system can overcome the challenges associated with this costly category

Gregory K. Bell, PhD
Shannon A. Baumann, MS

There was little difference between the options in terms of the frequency and cost of return visits. Patients receiving one-stage reconstructions returned slightly less often for breast-related services during the first 18 months after reconstruction, but the difference was not statistically significant.

Navin K. Singh, MD
Nancy L. Reaven, MA
Susan E. Funk, MBA

Legislation & Regulation
The SGR, ill-conceived and continually bypassed, may be nearing the end of its pathetic, useless life
John Carroll
Plan Watch

The insurer studies exactly what works and why in studying two programs that battle diabetes

Frank Diamond
Tomorrow's Medicine

This population can benefit from Juxtapid and Kynamro, but the cost is not addressed by health reform

Thomas Morrow, MD